P. Carmeliet and R. K. Jain, Angiogenesis in cancer and other diseases, Nature, vol.407, issue.6801, pp.249-57, 2000.

N. Ferrara, R. D. Mass, C. Campa, and R. Kim, Targeting VEGF-A to treat cancer and agerelated macular degeneration, Annu Rev Med, vol.58, pp.491-504, 2007.

R. Roskoski, Vascular endothelial growth factor (VEGF) signaling in tumor progression, Crit Rev Oncol Hematol, vol.62, issue.3, pp.179-213, 2007.

N. Ferrara, H. P. Gerber, and J. Lecouter, The biology of VEGF and its receptors, Nat Med, vol.9, issue.6, pp.669-76, 2003.

H. L. Goel and A. M. Mercurio, VEGF targets the tumour cell, Nat Rev Cancer, vol.13, issue.12, pp.871-82

S. Lantuejoul, B. Constantin, H. Drabkin, C. Brambilla, J. Roche et al.,

, Expression of VEGF, semaphorin SEMA3F, and their common receptors neuropilins NP1

, NP2 in preinvasive bronchial lesions, lung tumours, and cell lines, J Pathol, vol.200, issue.3, pp.336-383, 2003.

R. E. Bachelder, A. Crago, J. Chung, M. A. Wendt, L. M. Shaw et al., Vascular endothelial growth factor is an autocrine survival factor for neuropilin-expressing breast carcinoma cells, Cancer Res, vol.61, issue.15, pp.5736-5776, 2001.

R. E. Bachelder, M. A. Wendt, and A. M. Mercurio, Vascular endothelial growth factor promotes breast carcinoma invasion in an autocrine manner by regulating the chemokine receptor CXCR4, Cancer Res, vol.62, issue.24, pp.7203-7209, 2002.

H. L. Goel, C. Chang, B. Pursell, I. Leav, S. Lyle et al., VEGF/neuropilin-2 regulation of Bmi-1 and consequent repression of IGF-IR define a novel mechanism of aggressive prostate cancer, Cancer Discov, vol.2, issue.10, pp.906-927

B. M. Lichtenberger, P. K. Tan, H. Niederleithner, N. Ferrara, P. Petzelbauer et al.,

, Autocrine VEGF signaling synergizes with EGFR in tumor cells to promote epithelial cancer development, Cell, vol.140, issue.2, pp.268-79

K. V. Lu, J. P. Chang, C. A. Parachoniak, M. M. Pandika, M. K. Aghi et al.,

, VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex, Cancer Cell, vol.22, issue.1, pp.21-35

M. J. Pajares, J. Agorreta, M. Larrayoz, A. Vesin, T. Ezponda et al., Expression of tumor-derived vascular endothelial growth factor and its receptors is associated with outcome in early squamous cell carcinoma of the lung, J Clin Oncol, vol.30, issue.10, pp.1129-1165

C. J. Robinson and S. E. Stringer, The splice variants of vascular endothelial growth factor (VEGF) and their receptors, J Cell Sci, vol.114, pp.853-65, 2001.

D. O. Bates, T. G. Cui, J. M. Doughty, M. Winkler, M. Sugiono et al.,

, VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is downregulated in renal cell carcinoma, Cancer Res, vol.62, issue.14, pp.4123-4154, 2002.

M. R. Ladomery, S. J. Harper, and D. O. Bates, Alternative splicing in angiogenesis: the vascular endothelial growth factor paradigm, Cancer Lett, vol.249, issue.2, pp.133-175, 2007.

S. Harris, M. Craze, J. Newton, M. Fisher, D. T. Shima et al., Do antiangiogenic VEGF (VEGFxxxb) isoforms exist? A cautionary tale, PLoS One, vol.7, issue.5, p.35231

R. Catena, L. Larzabal, M. Larrayoz, E. Molina, J. Hermida et al.,

. Vegf-;-b and . Vegf, )b are weakly angiogenic isoforms of VEGF-A. Mol Cancer, vol.9, p.320

H. Xin, C. Zhong, E. Nudleman, and N. Ferrara, Evidence for Pro-angiogenic Functions of VEGF-Ax, Cell, vol.167, issue.1, pp.275-84, 2016.

J. Woolard, W. Y. Wang, H. S. Bevan, Y. Qiu, L. Morbidelli et al.,

, VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of